HDAC Inhibitors-New Generation of Target Specific Treatment

Author(s): A. V. Chavan, R. R. Somani.

Journal Name: Mini-Reviews in Medicinal Chemistry

Volume 10 , Issue 13 , 2010

Abstract:

Histone Deacetylases (HDACs) enzymes are critical in regulating gene expression and transcription. They also play a fundamental role in regulating cellular activities such as cell proliferation, survival and differentiation. Inhibition of HDACs has generated many fascinating results including a new strategy in human cancer therapy. HDAC Inhibitors (HDACIs) like SAHA, TSA are emerging as new promising drugs for various anti-inflammatory and CNS-disorders. This review, along with chemical classification, emphasizes on the therapeutic potential of various HDACIs against different diseases.

Keywords: Histone Deacetylase, HDAC inhibitor, chemistry, therapeutic applications, Enzyme Histone acetyltransferases, HAT, Class III HDACs, sirtuins, nu-clear receptor co-repressor, N-coR, Silencing Mediator, Thyroid receptors, SMRT, HDAC enzyme, aliphatic chain, Large hydrophobic region, Hydroxamic acids, trichostatin, TSA, suberoylanilide hydroxamic acid, SAHA, oxamflatin, Cyclic tetrapeptides, Benzamides, MS-27-275, Short-chain fatty acids, butyrates, Streptomyces hygro-scopicus, NVP-LAQ824, LAQ824, PDX 101, LDH589, Depsipeptide FK228, Chromobacterium violaceum, Apicidin, tubacin, Vorinostat, suberoylanilide hy-droxamic acid, Valproic acid, VPA, Trichostatin A

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 10
ISSUE: 13
Year: 2010
Page: [1263 - 1276]
Pages: 14
DOI: 10.2174/13895575110091263
Price: $58

Article Metrics

PDF: 17